PNO1 and hepatocellular carcinoma: In conclusion, this research critically evaluates PNO1 as a negative modulator of ferroptosis and provides a potential therapeutic strategy that targets PNO1 to strengthen sorafenib sensitivity against ferroptosis in HCC.